How much funding has Autifony Therapeutics raised?

Autifony Therapeutics has raised $37.0M in total funding, most recently a Extension Round.

Who are Autifony Therapeutics's investors?

Autifony Therapeutics's investors include SV Life Sciences, Innovate UK, Imperial Innovations, Pfizer Ventures, International Biotechnology Trust, GSK.

When was Autifony Therapeutics founded?

Autifony Therapeutics was founded in 2011.

Where is Autifony Therapeutics headquartered?

Autifony Therapeutics is headquartered in Stevenage, United Kingdom.

What industry is Autifony Therapeutics in?

Autifony Therapeutics operates in Biotech, Healthcare.

How many employees does Autifony Therapeutics have?

Autifony Therapeutics has 11-50 employees.

Autifony Therapeutics

Dedicated to developing new drugs to treat rare CNS disorders using pioneering science

Stevenage, United Kingdom · Founded 2011 · $37.0M raised

Biotech

Healthcare

Headquarters: Stevenage
Employees: 11–50
Founded: 2011
Business Model: B2B

Website: autifony.com
Total Funding: $37.0M
Last Round: $11.2M Extension RoundJul 2015
Rounds: 4

About

Autifony Therapeutics is a clinical-stage biotechnology company headquartered at Stevenage Bioscience Catalyst in the UK, founded in 2011. The company is dedicated to developing new medicines for rare genetic central nervous system (CNS) disorders by deploying its pioneering ion channel drug discovery platform. Autifony focuses on conditions including Fragile X Syndrome, advancing a neuroscience pipeline through strategic partnerships and collaborations with leading research institutions, and has been recognized as one of the UK's fastest-growing private biotech companies.

Summary

Autifony Therapeutics is a Biotech company based in Stevenage, United Kingdom, founded in 2011. It has raised $37.0M in total across 4 rounds, most recently a $11.2M Extension Round round in Jul 2015. Investors include SV Life Sciences, Innovate UK and Imperial Innovations.